INVIMA-Ready MedTech Dossier Checklist for First-in-Human Studies in Colombia

For a leading MedTech startup, Colombia can be an attractive setting for a first-in-human or early-feasibility study. The opportunity, however, is not created by a single form or approval letter. It depends on whether the sponsor presents a coherent story about intended use, risk, clinical need, participant protection, and operational control.

An INVIMA-ready dossier is therefore more than a document folder. It is a cross-functional quality system that allows the regulator, ethics committee, investigators, and import team to reach the same conclusion from the same evidence. The following checklist is designed for sponsors preparing an early-stage medical device study in Colombia. Requirements can change, so the current INVIMA forms and instructions should always be confirmed before filing.

1. Start with the intended use and risk story

The first quality gate is a short, precise statement of what the device is intended to do in the study and what the study is not designed to prove. Define the target population, clinical setting, operator, use procedure, expected benefit, and foreseeable hazards. Then connect each claim to a source of evidence.

This discipline prevents a common early-stage problem: the protocol describes a feasibility objective, while the technical file reads like a marketing submission. A first-in-human dossier should be candid about uncertainty and show how the investigation will manage it.

• Define the study purpose: distinguish feasibility, initial safety, usability, and exploratory performance objectives.
• Map the risk profile: link hazards and mitigations to the risk-management file and to monitoring activities.
• Clarify the use environment: describe the procedure, training assumptions, accessories, maintenance, and conditions that could affect performance.
• Identify evidence gaps: explain which questions require clinical data because bench testing, literature, or comparable-device information is insufficient.

2. Build the Colombia-specific submission core

INVIMA’s clinical-investigation resources identify the GICASE group and publish current forms and checklists for medical-device studies. The page references Resolution 8430 of 1993 as the general framework for research involving human beings and lists a checklist for technical-concept requests involving prototype medical-device protocols and associated documents. Sponsors should use the current version of that checklist as the filing backbone rather than relying on a generic global template.

The dossier should be assembled as a controlled set of modules, with an index that makes review easy:

• Protocol and synopsis: objectives, design, population, eligibility criteria, endpoints, follow-up, stopping rules, statistical rationale, and deviation handling.
• Device and technical file: description, intended use, design overview, manufacturing controls, verification and validation results, software or electrical documentation where relevant, labeling, instructions for use, and traceability.
• Risk and clinical justification: risk analysis, residual-risk assessment, literature or comparable-device evidence, known limitations, and a clear explanation of why the proposed study is proportionate to the remaining uncertainty.
• Participant protection: informed-consent materials, participant information, privacy safeguards, compensation or treatment arrangements, insurance documentation where applicable, and safety-reporting procedures.
• Site and investigator package: qualifications, facilities, equipment, training, delegation, recruitment plan, monitoring approach, and the ethics committee pathway.

Use a document matrix to show where each requirement is answered. If a requirement is not applicable, state why and identify the supporting rationale. An unexplained blank looks like an omission; a documented rationale shows control.

3. Treat ethics, imports, and site readiness as one workstream

Regulatory submission is only one part of activation. A technically complete dossier can still lose time if the ethics committee receives a different protocol version, the site is not trained on the final instructions, or the investigational shipment cannot be cleared. Sponsors should manage these dependencies in a single readiness plan.

• Synchronize versions: the protocol, consent form, investigator materials, labels, and training deck should use the same device description, risks, endpoints, and amendment status.
• Prepare the ethics package early: confirm committee submission windows, local language needs, investigator signatures, participant-facing readability, and the process for reporting serious adverse events.
• Plan import readiness: confirm the responsible local party, customs documentation, product classification, declared value, packing list, serial or lot traceability, storage conditions, and return or destruction process.
• Test site execution: rehearse device receipt, quarantine, accountability, calibration or setup, troubleshooting, use, cleaning, and post-procedure documentation before the first participant visit.

This approach also improves responses to information requests. When a reviewer asks how a risk is controlled, the sponsor can point to the same control in the technical file, protocol, training record, and monitoring plan.

4. Run a sponsor-side quality-control gate

Before filing, conduct a structured review that is independent of the person who assembled the first draft. The goal is not to make the dossier longer. It is to eliminate contradictions that create avoidable clarification cycles.

• Compare the device name used internally with the generic description used in participant materials and shipment documents.
• Reconcile every primary and secondary endpoint with the analysis plan, case-report forms, and monitoring metrics.
• Check that every residual risk has a mitigation, a participant-facing disclosure, and a safety signal or escalation pathway.
• Verify that investigator responsibilities, sponsor responsibilities, and vendor responsibilities are explicit.
• Confirm that translations preserve technical meaning and that the controlled English master is traceable.
• Prepare a response log with an owner, due date, evidence reference, and final approval for each question.

The best dossier is not the one with the most pages. It is the one a reviewer can navigate quickly, understand without inference, and assess against the study’s actual risk. For a leading MedTech startup, that clarity is a competitive operational advantage: it protects participant safety while reducing rework across regulatory, ethics, clinical, and logistics teams.

FAQ: INVIMA-ready MedTech dossiers

Does a global clinical-investigation package need a Colombia-specific adaptation?

Yes. A global core can reduce duplication, but the sponsor still needs a Colombia-specific regulatory and ethics annex. Adapt the local forms, language, responsible parties, participant materials, import plan, and explanations of how foreign evidence applies to the Colombian setting.

When should import planning begin?

Begin during protocol and site planning, not after approval. Classification, local responsibility, documentation, storage, and return or destruction decisions can affect the feasibility of the study and should be reflected in the operational plan.

What is the most common avoidable dossier weakness?

Inconsistency. Differences in device description, endpoint definitions, risk language, document versions, or responsibilities create questions that are preventable with a cross-document matrix and an independent quality-control review.